Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Net Income: 2022-2025

Historic Net Income for ARS Pharmaceuticals (SPRY) over the last 4 years, with Sep 2025 value amounting to -$53.2 million.

  • ARS Pharmaceuticals' Net Income fell 144.58% to -$53.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.8 million, marking a year-over-year decrease of 50.04%. This contributed to the annual value of $8.0 million for FY2024, which is 114.71% up from last year.
  • Per ARS Pharmaceuticals' latest filing, its Net Income stood at -$53.2 million for Q3 2025, which was down 11.72% from -$47.6 million recorded in Q2 2025.
  • ARS Pharmaceuticals' 5-year Net Income high stood at $47.2 million for Q4 2024, and its period low was -$53.2 million during Q3 2025.
  • Moreover, its 3-year median value for Net Income was -$18.7 million (2023), whereas its average is -$19.0 million.
  • In the last 5 years, ARS Pharmaceuticals' Net Income tumbled by 224.76% in 2023 and then skyrocketed by 561.54% in 2024.
  • Over the past 4 years, ARS Pharmaceuticals' Net Income (Quarterly) stood at -$15.4 million in 2022, then skyrocketed by 33.78% to -$10.2 million in 2023, then skyrocketed by 561.54% to $47.2 million in 2024, then crashed by 144.58% to -$53.2 million in 2025.
  • Its last three reported values are -$53.2 million in Q3 2025, -$47.6 million for Q2 2025, and -$37.2 million during Q1 2025.